- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04852419
A PHASE 1B STUDY OF ZN-C5 IN CHINESE SUBJECTS
August 10, 2022 updated by: Zentera Therapeutics HK Limited
A PHASE 1B STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF ZN-C5 IN CHINESE SUBJECTS WITH ADVANCED BREAST CANCER
The aim of this phase 1b study in Chinese patients with ER+/Her2- advanced breast cancer is to evaluate the safety and tolerability of ZN-c5 at dose of 50 mg and 150 mg QD well tolerance established in the previous oversea study in non-Chinese patients.
Study Overview
Detailed Description
Hormone receptor-positive, HER2-negative breast cancer is the most common subset of breast cancer.
The estrogen receptor (ER) in these patients is a key driver of disease progression, and the primary reason for relapse in these patients is that endocrine therapies are only partially effective, typically causing cell cycle arrest rather than cell death.
As a result, secondary resistance to endocrine therapy is a major clinical challenge.
ZN-c5 is a novel and potent ZN-c5 is a novel and potent selective estrogen receptor degrader with oral bioavailability and strong activity in estrogen-dependent and tamoxifen-resistant tumor models.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Shanghai, China
- Fudan University Cancer Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female
- Age ≥ 18 years
- Menopausal Status [Female subjects]
- Histologically or cytologically confirmed diagnosis of advanced adenocarcinoma of the breast, not amenable to any potential curative intervention
- Estrogen Receptor (ER) positive disease
- Human Epidermal Growth Factor Receptor 2 (HER2) negative disease
- Refractory to or intolerant of established therapy(ies) known to provide clinical benefit for their malignancy
- Prior Hormonal Therapy:
- Documented prior response to endocrine therapy for advanced or metastatic disease (SD, PR, or CR) lasting > 6 months24 weeks or disease recurrence after at least 24 months of adjuvant endocrine treatment.
- Prior Chemotherapy: Up to 2 prior lines of chemotherapy for the treatment of advanced breast cancer
- Prior treatment with a CDK4/6 inhibitor is allowed
- Evaluable or measurable disease per RECIST v1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1
- All acute toxic effects of any prior anti-tumor therapy resolved to Grade ≤ 1 or baseline (with the exception of alopecia [any grade permitted])
- Adequate organ function
- [Premenopausal and perimenopausal female subjects]: Negative serum pregnancy test
- Male and female subjects of childbearing potential or partners of subjects who engage in intercourse must agree to use protocol specified method(s) of contraception.
Exclusion Criteria:
- Any of the following within the specified window prior to the first dose of study drug
- Prior hematopoietic stem cell or bone marrow transplantation
- Prior radiotherapy to > 25% of bone marrow
- Brain metastases that require immediate treatment or are clinically or radiologically unstable (i.e., have been stable for < 1 month). If receiving steroids, subjects must be receiving a stable to decreasing corticosteroid dose during at least 1 week before enrollment.
- Leptomeningeal disease that requires or is anticipated to require immediate treatment.
- Presence of life-threatening metastatic visceral disease or symptomatic pulmonary lymphangitic spread
- Other known active cancer(s) likely to require treatment in the next year that would impact the assessment of any study endpoints
- [Female subjects]: Pregnant or breast-feeding
- Unexplained symptomatic endometrial disorders (including, but not limited to endometrial hyperplasia, dysfunctional uterine bleeding, or cysts)
- Impairment of gastrointestinal (GI) absorption for oral medications
- Nausea, vomiting, or diarrhea > Grade 1
- Myocardial infarction, symptomatic congestive heart failure (NYHA > Class II), unstable angina, or serious uncontrolled cardiac arrhythmia within the last 6 months
- QTc interval > 480 msec (based on the mean value of the triplicate ECGs), family or personal history of long or short QT syndrome, Brugada syndrome or history of Torsade de Pointes
- Concurrent use of food or drugs known to be moderate or strong CYP3A or CYP2C9 inducers and moderate or strong CYP3A4 or CYP2C9 inhibitors.
- Positive serum virological tests (HBsAg, HCV-AB, HIV-AB, TP-AB) at screening stage will be excluded.
- Any clinically significant disorder, condition, or disease that, in the opinion of the Investigator or Medical Monitor would pose a risk to subject safety or interfere with the study evaluations, procedures, or completion
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ZN-c5 50mg QD dose cohort
Phase 1b trial of monotherapy cohort with ZN-c5 as single agent will be evaluated with ZN-c5 50 mg administered orally, once daily.
Safety lead in phase will be applied.
|
ZN-c5
|
Experimental: Zn-c5 150mg QD dose cohort
Once safety and tolerability are established in ZN-c5 150 mg Dose QD in Chinese population, then it is possible to initiate the second monotherapy cohort with 150 mg QD or alternative dose well established in oversea population for preliminary efficacy and safety.
|
ZN-c5
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Observed Dose Limited Toxicities (DLTs) in safety lead in phase
Time Frame: At the end of Cycle 1 (each cycle is 28 days)
|
Safety lead in phase at dose of 50 mg QD: Determine a tolerated dose for ZN-c5 in monotherapy
|
At the end of Cycle 1 (each cycle is 28 days)
|
Incidence of treatment-emergent adverse events
Time Frame: until 30 days after the last dose of study drug
|
Investigate the safety and tolerability of dose of 50 mg QD of ZN-c5
|
until 30 days after the last dose of study drug
|
Incidence of treatment-emergent adverse events
Time Frame: until 30 days after the last dose of study drug
|
Investigate the safety and tolerability of dose of 150 mg QD of ZN-c5
|
until 30 days after the last dose of study drug
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CBR (CR [+ PR] + SD ≥ 24 weeks).
Time Frame: 2 year
|
Investigate the preliminary antitumor activity (clinical benefit rate [CBR]) for ZN-c5 as a monotherapy using Response Evaluation Criteria in Solid Tumors (RECIST v.1.1)
as assessed by investigators.
|
2 year
|
bjective Response Rate (ORR)
Time Frame: 2 year
|
Assess preliminary antitumor activity of ZN-c5 alone by Objective Response Rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST v.1.1)
as assessed by investigators.
|
2 year
|
Duration of Response (DOR)
Time Frame: 2 year
|
Assess preliminary antitumor activity of ZN-c5 alone by Duration of Response (DOR) using Response Evaluation Criteria in Solid Tumors (RECIST v.1.1)
as assessed by investigators.
|
2 year
|
Progression-Free Survival (PFS)
Time Frame: 2 year
|
Assess preliminary antitumor activity of ZN-c5 alone by Progression-Free Survival (PFS) using Response Evaluation Criteria in Solid Tumors (RECIST v.1.1)
as assessed by investigators.
|
2 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 31, 2021
Primary Completion (Actual)
June 23, 2022
Study Completion (Actual)
June 23, 2022
Study Registration Dates
First Submitted
April 11, 2021
First Submitted That Met QC Criteria
April 15, 2021
First Posted (Actual)
April 21, 2021
Study Record Updates
Last Update Posted (Actual)
August 11, 2022
Last Update Submitted That Met QC Criteria
August 10, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- c5ZTCN100
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Neoplasms
-
Seagen Inc.CompletedTriple Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms | HER2 Positive Breast Neoplasms | HER2 Mutations Breast NeoplasmsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Celgene CorporationTerminatedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
G1 Therapeutics, Inc.TerminatedBreast Cancer | Breast Neoplasm | Triple-Negative Breast Cancer | Triple-Negative Breast NeoplasmsUnited States, Bulgaria, Croatia, Slovenia, Serbia, Belgium, North Macedonia, Slovakia
-
Emory UniversityEisai Inc.TerminatedBreast Cancer | Breast Neoplasms | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Tumors, BreastUnited States
-
Dana-Farber Cancer InstituteConquer Cancer FoundationRecruitingBreast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Inflammatory Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of BreastUnited States
-
GlaxoSmithKlineCompletedNeoplasms, BreastUnited States, Spain, Israel, Canada, Belgium, United Kingdom, France, Tunisia
-
GlaxoSmithKlineCompletedNeoplasms, BreastUnited States, Canada, Germany, Spain, Taiwan, Belgium, Philippines, Israel, Hong Kong, Thailand, Pakistan, Russian Federation, Italy, Romania, China, France, Peru, United Kingdom, Czech Republic, Australia, Chile, Korea, Republic of and more
-
Oslo University HospitalKarolinska Institutet; Hoffmann-La Roche; Rigshospitalet, Denmark; Helse Stavanger... and other collaboratorsCompletedTriple Negative Breast Cancer | Cancer, BreastNorway, Denmark
-
MedSIRHoffmann-La RocheCompletedAdvanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast CancerSpain, France, United Kingdom, Germany, Italy
Clinical Trials on ZN-c5
-
Zeno Alpha Inc.Completed
-
Zeno Alpha Inc.CompletedBreast CancerUnited States, Australia, Bosnia and Herzegovina
-
Zeno Alpha Inc.CompletedBreast CancerUnited States, Poland
-
Zeno Alpha Inc.CompletedBreast CancerUnited States, Belarus, Bosnia and Herzegovina, Czechia, Hungary, Lithuania, Russian Federation, Serbia, Ukraine
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnAnatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma | Stage III Fallopian Tube Cancer AJCC v8 | Stage III Ovarian Cancer AJCC v8 | Stage III Primary Peritoneal Cancer AJCC v8 | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary... and other conditionsUnited States
-
K-Group Alpha, Inc., a wholly owned subsidiary...RecruitingAcute Myeloid Leukemia (AML)United States
-
Coloplast A/SCompletedIntermittent Urethral CatheterizationDenmark
-
University of PittsburghActive, not recruitingIntervertebral Disc DegenerationUnited States
-
Bionor Immuno ASCompleted
-
Marmara UniversityNot yet recruiting